iRhythm Technologies (NASDAQ:IRTC) Announces Quarterly Earnings Results

iRhythm Technologies (NASDAQ:IRTC) released its quarterly earnings data on Thursday. The company reported $0.58 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.62, FiscalAI reports. iRhythm Technologies had a negative return on equity of 10.26% and a negative net margin of 3.53%.The firm had revenue of $224.17 million during the quarter, compared to analyst estimates of $219.30 million. During the same quarter in the prior year, the firm posted ($0.32) earnings per share. The business’s quarterly revenue was up 20.1% compared to the same quarter last year.

Here are the key takeaways from iRhythm Technologies’ conference call:

• Q2 revenue rose 20.1% to $224.2 million, marking the seventh consecutive quarter of more than 20% growth. Adjusted EBITDA margin reached 19.3%, free cash flow was a record $37.5 million, and adjusted net income improved to $19.3 million.
• iRhythm raised its 2026 outlook to $880 million-$890 million in revenue and a 13%-14% adjusted EBITDA margin, citing sustained volume growth, operating efficiencies, and disciplined expense management.
• The pending VitalConnect acquisition is intended to broaden iRhythm’s MCT offering and add capabilities in inpatient monitoring, hospital-to-home care, remote patient monitoring, and multi-vital sensing. Management expects revenue contribution beginning in 2027 and believes the combined company can reach its previously stated 15% adjusted EBITDA margin target in 2027.
• FDA clearance of iRhythm’s third-generation algorithm could reduce technician review time by up to 50% and generate approximately $100 million in cumulative cost savings over five years after its planned first-half 2027 launch.
• Key execution and regulatory risks remain, including the pending FDA warning-letter resolution, HSR review and integration of VitalConnect, and continued uncertainty around the timing of Zio MCT clearance. The company also agreed to pay $50 million to settle litigation with Baxter, while a June cybersecurity incident involved data exfiltration despite no reported material operational or financial impact.

iRhythm Technologies Trading Up 2.9%

NASDAQ:IRTC traded up $3.62 during trading hours on Thursday, hitting $128.12. The company had a trading volume of 1,205,295 shares, compared to its average volume of 524,691. The company has a market capitalization of $4.21 billion, a PE ratio of -148.98 and a beta of 1.30. The stock has a 50-day moving average price of $114.76 and a 200 day moving average price of $124.55. iRhythm Technologies has a 52 week low of $100.85 and a 52 week high of $212.00. The company has a debt-to-equity ratio of 4.03, a current ratio of 5.17 and a quick ratio of 4.98.

Insiders Place Their Bets

In other news, Director Abhijit Y. Talwalkar purchased 5,312 shares of the stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $10.71 per share, with a total value of $56,891.52. Following the acquisition, the director directly owned 25,611 shares of the company’s stock, valued at $274,293.81. This represents a 26.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.98% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Measured Wealth Private Client Group LLC purchased a new position in iRhythm Technologies during the third quarter valued at approximately $30,000. Employees Retirement System of Texas bought a new stake in shares of iRhythm Technologies during the 3rd quarter valued at $36,000. Smartleaf Asset Management LLC lifted its stake in shares of iRhythm Technologies by 63.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 323 shares of the company’s stock valued at $58,000 after buying an additional 125 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new position in iRhythm Technologies in the 3rd quarter worth $69,000. Finally, Kestra Advisory Services LLC purchased a new stake in iRhythm Technologies in the 4th quarter worth $71,000.

Analysts Set New Price Targets

IRTC has been the subject of a number of recent analyst reports. Bank of America lowered their price target on shares of iRhythm Technologies from $225.00 to $180.00 and set a “buy” rating for the company in a report on Monday, May 18th. Canaccord Genuity Group decreased their price objective on shares of iRhythm Technologies from $180.00 to $152.00 and set a “buy” rating on the stock in a research report on Monday, June 1st. The Goldman Sachs Group decreased their price objective on shares of iRhythm Technologies from $184.00 to $147.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Weiss Ratings raised shares of iRhythm Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 18th. Finally, Wall Street Zen upgraded shares of iRhythm Technologies from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $184.71.

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.